Only PARP inhibitor to improve overall survival
vs enzalutamide or abiraterone in the biomarker-based subset of
prostate cancer patients with BRCA1/2 or ATM mutations
Approximately 20-30% of men with mCRPC have an
HRR gene-mutation
AstraZeneca and Merck & Co., Inc.,
Kenilworth, NJ, US (Merck: known as MSD outside the US and Canada)
today announced that LYNPARZA® (olaparib) has been approved in the
US for the treatment of adult patients with deleterious or
suspected deleterious germline or somatic homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant prostate
cancer (mCRPC) who have progressed following prior treatment with
enzalutamide or abiraterone. Patients will be selected for therapy
based on an FDA-approved companion diagnostic for LYNPARZA.
The approval by the US Food and Drug Administration (FDA) was
based on results from the Phase III PROfound trial, which were
published in the New England Journal of Medicine.
Prostate cancer is the second most common cancer in men and
despite an increase in the number of available therapies for men
with mCRPC, five-year survival remains low. HRR gene mutations
occur in approximately 20%-30% of patients with mCRPC.
Maha Hussain, one of the Principal Investigators of the PROfound
trial and deputy director of the Robert H. Lurie Comprehensive
Cancer Center of Northwestern University, said: “Prostate cancer
has lagged behind other solid tumors in the era of precision
medicine. I am thrilled by the approval of LYNPARZA which now
brings a molecularly targeted treatment to men with HRR
gene-mutated metastatic castration-resistant prostate cancer in the
US. The PROfound trial was an international effort and I want to
thank the patients, their families, the investigators and their
teams involved in making it possible.”
Dave Fredrickson, Executive Vice President, Oncology Business
Unit, said: “Today marks the first approval for LYNPARZA in
prostate cancer. In the PROfound trial, LYNPARZA more than doubled
median radiographic progression-free survival and is the only PARP
inhibitor to improve overall survival, versus enzalutamide or
abiraterone for men with BRCA or ATM mutations. These results
further establish that genomic testing for HRR mutations should be
a critical step for the diagnosis and determination of treatment
options for men with advanced prostate cancer.”
Roy Baynes, Senior Vice President and Head of Global Clinical
Development, Chief Medical Officer, Merck Research Laboratories,
said, “LYNPARZA is the only PARP inhibitor approved with Phase III
data for men with HRR gene-mutated metastatic castration-resistant
prostate cancer. This approval highlights the importance of genomic
testing to identify treatment options for men in this patient
population. We are proud to work in collaboration with AstraZeneca
toward our overall goal of improving outcomes for patients.”
The primary endpoint of the trial was radiographic
progression-free survival (rPFS) in men with BRCA1/2 or ATM gene
mutations, a subpopulation of HRR gene mutations. Results showed
LYNPARZA reduced the risk of disease progression or death by 66%
(equal to a hazard ratio of 0.34; p-value <0.0001) and improved
rPFS to a median of 7.4 months versus 3.6 months with enzalutamide
or abiraterone.
LYNPARZA also showed an rPFS benefit in the overall HRR
gene-mutated trial population, a key secondary endpoint, and
reduced the risk of disease progression or death by 51% (equal to a
hazard ratio of 0.49; p-value <0.0001) and improved rPFS to a
median of 5.8 months versus 3.5 months with enzalutamide or
abiraterone.
Additional results announced on April 24, 2020 demonstrated a
statistically significant and clinically meaningful improvement in
the key secondary endpoint of overall survival (OS) with LYNPARZA
versus abiraterone or enzalutamide in men with mCRPC and BRCA1/2 or
ATM gene mutations. Results showed LYNPARZA reduced the risk of
death by 31% (equal to a hazard ratio of 0.69 and p-value 0.0175)
and improved OS to a median of 19.1 months versus 14.7 months with
enzalutamide or abiraterone.
Fatal adverse reactions occurred in 4% of patients treated with
LYNPARZA. These included pneumonia (1.2%), cardiopulmonary failure
(0.4%), aspiration pneumonia (0.4%), intestinal diverticulum
(0.4%), septic shock (0.4%), Budd-Chiari Syndrome (0.4%), sudden
death (0.4%), and acute cardiac failure (0.4%). Serious adverse
reactions occurred in 36% of patients receiving LYNPARZA. Serious
adverse reactions in ≥2% were anemia (9%), pneumonia (4%),
pulmonary embolism (2%), fatigue/asthenia (2%), and urinary tract
infection (2%).
The most common adverse reactions (Grade 1-4) occurring in ≥10%
in the LYNPARZA arm (N=256) were anemia (46%), nausea (41%),
fatigue including asthenia (41%), decreased appetite (30%),
diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%)
and dyspnea (10%).
In addition, venous thromboembolic events, including pulmonary
embolism, occurred in 7% of patients with metastatic
castration-resistant prostate cancer who received LYNPARZA plus
androgen deprivation therapy (ADT) compared to 3.1% of patients
receiving enzalutamide or abiraterone plus ADT in the PROfound
study. Patients receiving LYNPARZA and ADT had a 6% incidence of
pulmonary embolism compared to 0.8% of patients treated with ADT
plus either enzalutamide or abiraterone.
AstraZeneca and Merck are testing LYNPARZA in additional trials
in prostate cancer including the ongoing Phase III PROpel trial as
a 1st-line treatment in combination with abiraterone acetate for
patients with mCRPC versus abiraterone acetate alone.
Financial Considerations
Following this approval for LYNPARZA in the US, AstraZeneca will
receive a regulatory milestone payment from Merck of $35m,
anticipated to be booked as Collaboration Revenue by the Company
during the second quarter of 2020.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
There are no contraindications for LYNPARZA.
WARNINGS AND PRECAUTIONS
Myelodysplastic Syndrome/Acute Myeloid Leukemia
(MDS/AML): Occurred in <1.5% of patients exposed to LYNPARZA
monotherapy, and the majority of events had a fatal outcome. The
duration of therapy in patients who developed secondary MDS/AML
varied from <6 months to >2 years. All of these patients had
previous chemotherapy with platinum agents and/or other
DNA-damaging agents, including radiotherapy, and some also had a
history of more than one primary malignancy or of bone marrow
dysplasia.
Do not start LYNPARZA until patients have recovered from
hematological toxicity caused by previous chemotherapy (≤Grade 1).
Monitor complete blood count for cytopenia at baseline and monthly
thereafter for clinically significant changes during treatment. For
prolonged hematological toxicities, interrupt LYNPARZA and monitor
blood count weekly until recovery.
If the levels have not recovered to Grade 1 or less after 4
weeks, refer the patient to a hematologist for further
investigations, including bone marrow analysis and blood sample for
cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.
Pneumonitis: Occurred in <1% of patients exposed to
LYNPARZA, and some cases were fatal. If patients present with new
or worsening respiratory symptoms such as dyspnea, cough, and
fever, or a radiological abnormality occurs, interrupt LYNPARZA
treatment and initiate prompt investigation. Discontinue LYNPARZA
if pneumonitis is confirmed and treat patient appropriately.
Embryo-Fetal Toxicity: Based on its mechanism of action
and findings in animals, LYNPARZA can cause fetal harm. A pregnancy
test is recommended for females of reproductive potential prior to
initiating treatment.
Females
Advise females of reproductive potential of the potential risk
to a fetus and to use effective contraception during treatment and
for 6 months following the last dose.
Males
Advise male patients with female partners of reproductive
potential or who are pregnant to use effective contraception during
treatment and for 3 months following the last dose of LYNPARZA and
to not donate sperm during this time.
Venous Thromboembolic Events: Including pulmonary
embolism, occurred in 7% of patients with metastatic
castration-resistant prostate cancer who received LYNPARZA plus
androgen deprivation therapy (ADT) compared to 3.1% of patients
receiving enzalutamide or abiraterone plus ADT in the PROfound
study. Patients receiving LYNPARZA and ADT had a 6% incidence of
pulmonary embolism compared to 0.8% of patients treated with ADT
plus either enzalutamide or abiraterone. Monitor patients for signs
and symptoms of venous thrombosis and pulmonary embolism, and treat
as medically appropriate, which may include long-term
anticoagulation as clinically indicated.
ADVERSE REACTIONS—First-Line Maintenance BRCAm Advanced
Ovarian Cancer
Most common adverse reactions (Grades 1-4) in ≥10% of patients
in clinical trials of LYNPARZA in the first-line maintenance
setting for SOLO-1 were: nausea (77%), fatigue (67%),
abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%),
constipation (28%), upper respiratory tract
infection/influenza/nasopharyngitis/bronchitis (28%), dysgeusia
(26%), decreased appetite (20%), dizziness (20%), neutropenia
(17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%),
thrombocytopenia (11%), and stomatitis (11%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA in the first-line
maintenance setting for SOLO-1 were: decrease in
hemoglobin (87%), increase in mean corpuscular volume (87%),
decrease in leukocytes (70%), decrease in lymphocytes (67%),
decrease in absolute neutrophil count (51%), decrease in platelets
(35%), and increase in serum creatinine (34%).
ADVERSE REACTIONS—First-Line Maintenance Advanced Ovarian
Cancer in Combination with Bevacizumab
Most common adverse reactions (Grades 1-4) in ≥10% of patients
treated with LYNPARZA/bevacizumab compared to a ≥5% frequency for
placebo/bevacizumab in the first-line maintenance setting
for PAOLA-1 were: nausea (53%), fatigue (including asthenia)
(53%), anemia (41%), lymphopenia (24%), vomiting (22%) and
leukopenia (18%). In addition, the most common adverse reactions
(≥10%) for patients receiving LYNPARZA/bevacizumab irrespective of
the frequency compared with the placebo/bevacizumab arm were:
diarrhea (18%), neutropenia (18%), urinary tract infection (15%)
and headache (14%).
In addition, venous thromboembolic events occurred more commonly
in patients receiving LYNPARZA/bevacizumab (5%) than in those
receiving placebo/bevacizumab (1.9%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients for LYNPARZA in combination with bevacizumab in the
first-line maintenance setting for PAOLA-1 were:
decrease in hemoglobin (79%), decrease in lymphocytes (63%),
increase in serum creatinine (61%), decrease in leukocytes (59%),
decrease in absolute neutrophil count (35%) and decrease in
platelets (35%).
ADVERSE REACTIONS—Maintenance Recurrent Ovarian
Cancer
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in clinical trials of LYNPARZA in the maintenance setting
for SOLO-2 were: nausea (76%), fatigue (including asthenia)
(66%), anemia (44%), vomiting (37%), nasopharyngitis/upper
respiratory tract infection (URI)/influenza (36%), diarrhea (33%),
arthralgia/myalgia (30%), dysgeusia (27%), headache (26%),
decreased appetite (22%), and stomatitis (20%).
Study 19: nausea (71%), fatigue (including asthenia)
(63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory
tract infection (22%), constipation (22%), headache (21%),
decreased appetite (21%) and dyspepsia (20%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA in the maintenance
setting (SOLO-2/Study 19) were: increase in mean corpuscular
volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in
leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease
in absolute neutrophil count (51%/47%), increase in serum
creatinine (44%/45%), and decrease in platelets (42%/36%).
ADVERSE REACTIONS—Advanced gBRCAm Ovarian Cancer
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in clinical trials of LYNPARZA for advanced gBRCAm ovarian
cancer after 3 or more lines of chemotherapy (pooled from 6
studies) were: fatigue/asthenia (66%), nausea (64%), vomiting
(43%), anemia (34%), diarrhea (31%), nasopharyngitis/upper
respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia
(22%), decreased appetite (22%), and arthralgia/musculoskeletal
pain (21%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA for advanced gBRCAm
ovarian cancer (pooled from 6 studies) were: decrease in
hemoglobin (90%), mean corpuscular volume elevation (57%), decrease
in lymphocytes (56%), increase in serum creatinine (30%), decrease
in platelets (30%), and decrease in absolute neutrophil count
(25%).
ADVERSE REACTIONS—gBRCAm, HER2-Negative Metastatic Breast
Cancer
Most common adverse reactions (Grades 1-4) in ≥20% of patients
in OlympiAD were: nausea (58%), anemia (40%), fatigue
(including asthenia) (37%), vomiting (30%), neutropenia (27%),
respiratory tract infection (27%), leukopenia (25%), diarrhea
(21%), and headache (20%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in OlympiAD were: decrease in hemoglobin (82%),
decrease in lymphocytes (73%), decrease in leukocytes (71%),
increase in mean corpuscular volume (71%), decrease in absolute
neutrophil count (46%), and decrease in platelets (33%).
ADVERSE REACTIONS—First-Line Maintenance gBRCAm Metastatic
Pancreatic Adenocarcinoma
Most common adverse reactions (Grades 1-4) in ≥10% of patients
in clinical trials of LYNPARZA in the first-line maintenance
setting for POLO were: fatigue (60%), nausea (45%),
abdominal pain (34%), diarrhea (29%), anemia (27%), decreased
appetite (25%), constipation (23%), vomiting (20%), back pain
(19%), arthralgia (15%), rash (15%), thrombocytopenia (14%),
dyspnea (13%), neutropenia (12%), nasopharyngitis (12%), dysgeusia
(11%), and stomatitis (10%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA in the first-line
maintenance setting for POLO were: increase in serum
creatinine (99%), decrease in hemoglobin (86%), increase in mean
corpuscular volume (71%), decrease in lymphocytes (61%), decrease
in platelets (56%), decrease in leukocytes (50%), and decrease in
absolute neutrophil count (25%).
ADVERSE REACTIONS—HRR Gene-mutated Metastatic
Castration-Resistant Prostate Cancer
Most common adverse reactions (Grades 1-4) in ≥10% of patients
in clinical trials of LYNPARZA for PROfound were: anemia
(46%), fatigue (including asthenia) (41%), nausea (41%), decreased
appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia
(12%), cough (11%), and dyspnea (10%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of
patients in clinical trials of LYNPARZA for PROfound were:
decrease in hemoglobin (98%), decrease in lymphocytes (62%),
decrease in leukocytes (53%), and decrease in absolute neutrophil
count (34%).
DRUG INTERACTIONS
Anticancer Agents: Clinical studies of LYNPARZA with
other myelosuppressive anticancer agents, including DNA-damaging
agents, indicate a potentiation and prolongation of
myelosuppressive toxicity.
CYP3A Inhibitors: Avoid coadministration of strong or
moderate CYP3A inhibitors when using LYNPARZA. If a strong or
moderate CYP3A inhibitor must be coadministered, reduce the dose of
LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice,
Seville oranges, and Seville orange juice during LYNPARZA
treatment.
CYP3A Inducers: Avoid coadministration of strong or
moderate CYP3A inducers when using LYNPARZA.
USE IN SPECIFIC POPULATIONS
Lactation: No data are available regarding the presence
of olaparib in human milk, its effects on the breastfed infant or
on milk production. Because of the potential for serious adverse
reactions in the breastfed infant, advise a lactating woman not to
breastfeed during treatment with LYNPARZA and for 1 month after
receiving the final dose.
Pediatric Use: The safety and efficacy of LYNPARZA have
not been established in pediatric patients.
Hepatic Impairment: No adjustment to the starting dose is
required in patients with mild or moderate hepatic impairment
(Child-Pugh classification A and B). There are no data in patients
with severe hepatic impairment (Child-Pugh classification C).
Renal Impairment: No dosage modification is recommended
in patients with mild renal impairment (CLcr 51-80 mL/min estimated
by Cockcroft-Gault). In patients with moderate renal impairment
(CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice
daily. There are no data in patients with severe renal impairment
or end-stage renal disease (CLcr ≤30 mL/min).
INDICATIONS
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor
indicated:
First-Line Maintenance BRCAm Advanced Ovarian Cancer
For the maintenance treatment of adult patients with deleterious
or suspected deleterious germline or somatic BRCA-mutated (gBRCAm
or sBRCAm) advanced epithelial ovarian, fallopian tube, or primary
peritoneal cancer who are in complete or partial response to
first-line platinum-based chemotherapy. Select patients for therapy
based on an FDA-approved companion diagnostic for LYNPARZA.
First-Line Maintenance HRD-Positive Advanced Ovarian Cancer
in Combination with Bevacizumab
In combination with bevacizumab for the maintenance treatment of
adult patients with advanced epithelial ovarian, fallopian tube or
primary peritoneal cancer who are in complete or partial response
to first-line platinum-based chemotherapy and whose cancer is
associated with homologous recombination deficiency (HRD) positive
status defined by either:
- a deleterious or suspected deleterious BRCA mutation,
and/or
- genomic instability
Select patients for therapy based on an FDA-approved companion
diagnostic for LYNPARZA.
Maintenance Recurrent Ovarian Cancer
For the maintenance treatment of adult patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal cancer,
who are in complete or partial response to platinum-based
chemotherapy.
Advanced gBRCAm Ovarian Cancer
For the treatment of adult patients with deleterious or
suspected deleterious germline BRCA-mutated (gBRCAm) advanced
ovarian cancer who have been treated with 3 or more prior lines of
chemotherapy. Select patients for therapy based on an FDA-approved
companion diagnostic for LYNPARZA.
gBRCAm, HER2-Negative Metastatic Breast Cancer
For the treatment of adult patients with deleterious or
suspected deleterious gBRCAm, human epidermal growth factor
receptor 2 (HER2)-negative metastatic breast cancer who have been
treated with chemotherapy in the neoadjuvant, adjuvant, or
metastatic setting. Patients with hormone receptor (HR)-positive
breast cancer should have been treated with a prior endocrine
therapy or be considered inappropriate for endocrine therapy.
Select patients for therapy based on an FDA-approved companion
diagnostic for LYNPARZA.
First-Line Maintenance gBRCAm Metastatic Pancreatic
Cancer
For the maintenance treatment of adult patients with deleterious
or suspected deleterious gBRCAm metastatic pancreatic
adenocarcinoma whose disease has not progressed on at least 16
weeks of a first-line platinum-based chemotherapy regimen. Select
patients for therapy based on an FDA-approved companion diagnostic
for LYNPARZA.
HRR Gene-mutated Metastatic Castration-Resistant Prostate
Cancer
For the treatment of adult patients with deleterious or
suspected deleterious germline or somatic homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant prostate
cancer (mCRPC) who have progressed following prior treatment with
enzalutamide or abiraterone. Select patients for therapy based on
an FDA-approved companion diagnostic for LYNPARZA.
Please click here for complete Prescribing Information,
including Patient Information (Medication Guide).
NOTES TO EDITORS
About Metastatic Castration-Resistant Prostate Cancer
Prostate cancer is the second-most common cancer in men. An
estimated 191,930 men in the United States will be diagnosed with
prostate cancer in 2020. Development of prostate cancer is often
driven by male sex hormones called androgens, including
testosterone. mCRPC occurs when prostate cancer grows and spreads
to other parts of the body despite the use of androgen-deprivation
therapy to block the action of male sex hormones. Approximately
10-20% of men with prostate cancer will develop CRPC within five
years, and at least 84% of these men will have metastases at the
time of CRPC diagnosis. Of men with no metastases at CRPC
diagnosis, 33% are likely to develop metastases within two years.
Despite an increase in the number of available therapies for men
with mCRPC, five-year survival is low and extending survival
remains a key goal for treating these men.
About Homologous Recombination Repair (HRR) Mutations
HRR mutations occur in approximately 25% of patients with mCRPC.
HRR genes allow for accurate repair of damaged DNA in normal cells.
HRR deficiency (HRD) means the DNA damage cannot be repaired and
can result in normal cell death. This is different in cancer cells,
where a mutation in HRR pathways leads to abnormal cell growth and
therefore cancer. The inability to properly repair DNA damage leads
to genomic instability and contributes to cancer etiology. HRD is a
well-documented target for PARP inhibitors, such as LYNPARZA. PARP
inhibitors block a rescue DNA damage repair mechanism by trapping
DNA single-strand breaks which leads to replication fork stalling
causing their collapse and the generation of DNA double-strand
breaks which in turn lead to cancer cell death.
About PROfound
PROfound is a prospective, multi-center, randomized, open-label,
Phase III trial testing the efficacy and safety of LYNPARZA 300 mg
(two 150 mg tablets) twice daily versus enzalutamide or abiraterone
in patients with mCRPC who have progressed on prior treatment with
abiraterone or enzalutamide and have a qualifying tumor mutation in
BRCA1/2, ATM or one of 12 other genes involved in the HRR
pathway.
The trial was designed to analyze patients with HRRm genes in
two cohorts; the primary endpoint in those with mutations in
BRCA1/2 or ATM genes and then, if LYNPARZA showed clinical benefit,
a formal analysis was performed of the overall trial population of
patients with HRRm genes (BRCA1/2, ATM, CDK12 and 11 other HRRm
genes; key secondary endpoint).
Patients are selected for
treatment with LYNPARZA based on the following FDA-approved
companion diagnostics:
- FoundationOne CDx: to identify patients with HRR gene mutations
in prostate cancer tissue. FoundationOne CDx is a registered
trademark of Foundation Medicine, Inc.
- BRACAnalysis CDx: a germline test to identify patients with
BRCA1 and BRCA2 gene mutations. Myriad Genetics, Inc. owns and
commercializes BRACAnalysis CDx®.
About LYNPARZA® (olaparib)
LYNPARZA® (olaparib) is a
first-in-class PARP inhibitor and the first targeted treatment to
block DNA damage response (DDR) in cells/tumors harboring a
deficiency in homologous recombination repair, such as mutations in
BRCA1 and/or BRCA2. Inhibition of PARP with LYNPARZA leads to the
trapping of PARP bound to DNA single-strand breaks, stalling of
replication forks, their collapse and the generation of DNA
double-strand breaks and cancer cell death. LYNPARZA is being
tested in a range of PARP-dependent tumor types with defects and
dependencies in the DDR pathway.
LYNPARZA, which is being jointly developed and commercialized by
AstraZeneca and Merck, has the broadest and most advanced clinical
trial development program of any PARP inhibitor, and AstraZeneca
and Merck are working together to understand how it may affect
multiple PARP-dependent tumors as a monotherapy and in combination
across multiple cancer types. LYNPARZA is the foundation of
AstraZeneca’s industry-leading portfolio of potential new medicines
targeting DDR mechanisms in cancer cells.
About the AstraZeneca and Merck Strategic Oncology
Collaboration
In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth,
NJ, US, known as MSD outside the United States and Canada,
announced a global strategic oncology collaboration to co-develop
and co-commercialize LYNPARZA, the world’s first PARP inhibitor,
and other medicines, for multiple cancer types. Working together,
the companies will develop LYNPARZA and other medicines in
combination with other potential new medicines and as
monotherapies. Independently, the companies will develop LYNPARZA
and other medicines in combination with their respective PD-L1 and
PD-1 medicines.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a
quickly growing portfolio of new medicines that has the potential
to transform patients’ lives and the Company’s future. With at
least six new medicines to be launched between 2014 and 2020, and a
broad pipeline of small molecules and biologics in development, we
are committed to advance Oncology as a growth driver for
AstraZeneca focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative
partnerships and investments that accelerate the delivery of our
strategy, as illustrated by our investment in Acerta Pharma in
hematology.
By harnessing the power of four scientific platforms –
Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates – and by championing the development
of personalized combinations, AstraZeneca has the vision to
redefine cancer treatment and one day eliminate cancer as a cause
of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory & Immunology. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200520005224/en/
Media Inquiries Michele Meixell +1 302 885 2677 Brendan
McEvoy +1 302 885 2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024